Document Detail

Effects of kainic acid, quisqualic acid, and their antagonist, pCB-PzDA, on rat electrocorticograms and monoamine metabolite levels in rat striatum.
MedLine Citation:
PMID:  7513829     Owner:  NLM     Status:  MEDLINE    
The action of kainic acid (KA), quisqualic acid (QA), and 1-(4-chlorobenzoyl)-piperazine-2,3-dicarboxylic acid (pCB-PzDA) was investigated in the central nervous system of male Sprague Dawley rats. Intracerebroventricularly injected KA and QA (100 nmol) induced spike discharges, and pCB-PzDA (100 nmol) suppressed electrocorticograms for one hour. pCB-PzDA enhanced the KA-induced spike discharges and inhibited those induced by QA. 2,3-Di-hydroxyphenylacetic acid(DOPAC) and homovanillic acid (HVA) levels were increased transiently by 10 nmol and continuously by 100 nmol of KA. KA dose-dependently increased 5-hydroxyindoleacetic acid (5-HIAA) levels 2 hours after administration. While 10 nmol of QA slightly increased the HVA level, 100 nmol of QA significantly increased DOPAC, HVA, and 5-HIAA levels. DOPAC and HVA levels were increased by 100 nmol of pCB-PzDA, although this agent inhibited KA-induced increases in DOPAC, HVA, and 5-HIAA levels. On the other hand, while pCB-PzDA first inhibited QA-induced increases in DOPAC, HVA and 5-HIAA levels for one hour, DOPAC and HVA levels thereafter increased additively. These findings suggest that pCB-PzDA may act not only as a NMDA antagonist, but that it may also act directly on dopaminergic neurons.
H Kabuto; I Yokoi; S MoonSuk; M Yamamoto; A Mori
Related Documents :
9070639 - Differential effects of kainic acid on dopamine and serotonin metabolism in ventral and...
4010149 - Origin of positive transepithelial potential difference in early distal segments of rat...
1710099 - Altered serotonin activity in anorexia nervosa after long-term weight restoration. does...
2260859 - Stiff-man syndrome: a gabaergic autoimmune disorder with autoantigenic heterogeneity.
19453159 - (1)h nmr based metabonomics of human amniotic fluid for the metabolic characterization ...
1173549 - Palmitic acid and lecithin measurements in amniotic fluid.
894139 - Lipids of the anal sac secretions of the red fox, vulpes vulpes and of the lion, panthe...
18262699 - Usnic acid controls the acidity tolerance of lichens.
8738769 - Displacement of valproic acid and carbamazepine from protein binding in normal and urem...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurochemical research     Volume:  19     ISSN:  0364-3190     ISO Abbreviation:  Neurochem. Res.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-06-06     Completed Date:  1994-06-06     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  7613461     Medline TA:  Neurochem Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  267-74     Citation Subset:  IM    
Department of Neuroscience, Okayama University Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3,4-Dihydroxyphenylacetic Acid / metabolism
Biogenic Monoamines / metabolism*
Brain / drug effects,  metabolism*
Cerebral Cortex / drug effects,  physiology*
Chromatography, High Pressure Liquid
Corpus Striatum / drug effects,  metabolism,  physiology*
Electroencephalography / drug effects*
Homovanillic Acid / metabolism
Hydroxyindoleacetic Acid / metabolism
Kainic Acid / antagonists & inhibitors,  pharmacology*
Piperazines / pharmacology*
Quisqualic Acid / antagonists & inhibitors,  pharmacology*
Rats, Sprague-Dawley
Time Factors
Reg. No./Substance:
0/Biogenic Monoamines; 0/Piperazines; 102-32-9/3,4-Dihydroxyphenylacetic Acid; 306-08-1/Homovanillic Acid; 487-79-6/Kainic Acid; 52809-07-1/Quisqualic Acid; 54-16-0/Hydroxyindoleacetic Acid; 94856-91-4/1-(4-chlorobenzoyl)piperazine-2,3-dicarboxylic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Formation and persistence of DNA adducts in pouch skin fibroblasts and liver tissue of rats exposed ...
Next Document:  Palliative treatment of pancreatic carcinoma. Comparison between 2 successive observation periods